Akero Therapeutics

General Information


We are a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical need. Our initial focus is on nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. NASH is a leading cause for liver transplantation.

Employees: 8
Founded: 2017
Contact Information
Address 170 Harbor Way, 3rd Floor, South San Francisco, CA 94080, US
Phone Number (650)-487-6488
Web Address http://www.akerotx.com
View Prospectus: Akero Therapeutics
Financial Information
Market Cap $432.7mil
Revenues $0 mil (last 12 months)
Net Income $-87.2 mil (last 12 months)
IPO Profile
Symbol AKRO
Exchange NASDAQ
Shares (millions): 5.8
Price range $16.00 - $16.00
Est. $ Volume $92.0 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ Evercore ISI
CO-Managers Roth Capital Partners
Expected To Trade: 6/20/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change